Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.
Matthew Sanders
Advertisement
Matthew Sanders is vice-president, head of Global Drug Substance at GSK, Rixensart, Belgium.
Articles by Matthew Sanders
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
3
Everything to Know About Cell and Gene Therapy in 2025
4
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
5
